Search Results - Oncology

13 Results Sort By:
Novel Oncolytic Herpes Simplex Virus (oHSV) for Cancer Treatment
­ Researchers from UTHealth have developed a novel oncolytic viral therapy, oHSV-shPKR, which can inhibit tumor cells’ antiviral PKR activity, and increase oncolytic virus infection and replication in both oncolytic viral-resistant and sensitive cancer cells. This novel oHSV-shPKR therapy can significantly increase the anti-tumor immune response...
Published: 1/7/2022   |   Inventor(s):  
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Co-Administration of Oncolytic Herpes Simplex Virus (oHSV) with Cisplatin for Anti-Cancer Immunotherapy
­Researchers from UTHealth and Ohio State University College of Medicine have collaborated to investigate the impact of oHSV therapy in combination with platinum agents using platinum-resistant high-grade serous ovarian carcinoma (HGSOC) as well as platinum-resistant ovarian clear cell carcinoma models. More importantly, they have developed a novel...
Published: 1/7/2022   |   Inventor(s):  
Keywords(s):  
Category(s): Therapeutics, Oncology
Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use
­Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal a role for OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...
Published: 12/16/2021   |   Inventor(s):  
Keywords(s):  
Category(s): Diagnostics, Therapeutics, Biologics, Oncology
Peptides Targeting Chemotherapy-Resistant Metastatic Cancer Cells for Therapeutic and Diagnostic Use
Researchers at UTHealth have identified new molecules that selectively target metastatic cancer cells in mammals both in vitro and in vivo by screening a combinatorial library in a mouse mammary tumor model of spontaneous metastasis, and demonstrated their application as noninvasive imaging probes and vehicles for cytotoxic therapy delivery in preclinical...
Published: 12/16/2021   |   Inventor(s):  
Keywords(s):  
Category(s): Oncology, Therapeutics, Diagnostics
Monoclonal Antibodies Against Chitinase 3-like-1 (Chi3l1) for Therapeutic and Diagnostic Use
­Researchers at UTHealth have unveiled a critical role of Chi3l1 in hepatic platelet recruitment during acetaminophen (APAP)-induced liver injury (AILI) using murine models of AILI and concanavalin A (Con A)-induced hepatitis. Significantly, they have developed anti-Chi3l1 monoclonal antibodies and demonstrated the feasibility of targeting CHI3L1...
Published: 12/6/2021   |   Inventor(s): Zhiqiang An, Changqing (Cynthia) Ju
Keywords(s):  
Category(s): Biologics, Therapeutics, Oncology
Novel Fendiline Derivatives for the Treatment of KRAS Mutant Tumors
Novel Compounds and Methods of Use for the Treatment and Prevention of Cancer via Inhibition of the K-Ras Pathway Background: The Ras protein family members belong to a class of proteins called small GTPases and when activated by incoming signals, it subsequently switches on other genes involved in cell growth, differentiation, and survival. As a...
Published: 9/22/2020   |   Inventor(s):  
Keywords(s):  
Category(s): Oncology, Therapeutics
Monoclonal antibodies against human and mouse leptin for therapeutic and diagonostic use.
BackgroundLeptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was...
Published: 3/5/2020   |   Inventor(s): Zhiqiang An, Philipp Scherer, Ningyan Zhang
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics, Metabolism
Formulation of HDACi Loaded ß-Cyclodextrin-poly (ß-amino ester) Nanoparticles
Researchers have developed a novel formulation strategy to encapsulate molecules, including but not limited to histone deacetylase inhibitor (HDACi) drugs in nanoparticle networks composed of beta-cyclodextrin-poly(beta-amino esters). Advantages of this system include high loading capacity, increased in vivo tolerability, sustained release, and improved...
Published: 1/15/2020   |   Inventor(s): Rachael Sirianni
Keywords(s):  
Category(s): Drug Delivery, Therapeutics, Oncology
Monoclonal antibodies against human endotrophin for therapeutic and diagonostic use.
BackgroundStudies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through epithelial-mesenchymal...
Published: 1/10/2020   |   Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer
Keywords(s):  
Category(s): Biologics, Oncology, Therapeutics
Improved Antibody-Drug Conjugate Linker Compositions and Methods of Use
Faculty members at the University of Texas Health Science Center at Houston have developed a novel chemical linker for constructing antibody-drug conjugates (ADCs). While traditional ADC linkers can only load a single payload molecule, the developed linker has the ability to load two identical or different drug payloads. Doubling the number of payloads...
Published: 10/17/2019   |   Inventor(s): Kyoji Tsuchikama, Yasuaki Anami, Chisato Tsuchikama, Zhiqiang An, Ningyan Zhang
Keywords(s):  
Category(s): Research Materials, Oncology, Drug Delivery, Therapeutics, Biologics
1 2 
© 2022. All Rights Reserved. Powered by Inteum